Form 4: Cognition Therapeutics Director Ellen Richstone Acquires Shares and Stock Options

Director Ellen Richstone acquired 8,500 shares of common stock and stock options in Cognition Therapeutics, according to a recent SEC filing.

Summary

• On June 7, 2024, Ellen Richstone, a director of Cognition Therapeutics Inc., acquired 8,500 shares of common stock represented by restricted stock units (RSUs) and 8,500 stock options.
• The RSUs vest on the earlier of June 7, 2025, or the date of the Issuer's next annual meeting of stockholders, contingent upon continuous service as a director.
• The stock options, with an exercise price of $1.95, also vest on the earlier of June 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to continuous service as a director, and expire on June 7, 2034.
• Following the transaction, Richstone beneficially owns 24,500 shares of common stock.
• A Power of Attorney was executed on June 5, 2024, granting the Chief Executive Officer and Chief Financial Officer of Cognition Therapeutics, Inc. the authority to execute Forms 3, 4, and 5 on Richstone's behalf.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction report. The acquisition of shares and options could be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of shares and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the director's continuous service, suggesting a commitment to the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates